Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
Election of a Director
On May 12, 2019, the Board of Directors (the Board) elected Badrul A. Chowdhury, M.D. Ph.D., as a Class III director whose term will
expire at the Companys 2021 annual meeting of shareholders, effective immediately.
For his service on the Board, Dr. Chowdhury will receive
compensation as a
non-employee
director in accordance with the Companys
non-employee
director compensation practices described under the Director
Compensation section of the Companys definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2019.
There are no arrangements or understandings between Dr. Chowdhury and any other persons pursuant to which Dr. Chowdhury was named as a director.
Dr. Chowdhury is not a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation
S-K.
In connection with his election to the Board, Dr. Chowdhury will execute the Companys standard form of indemnification agreement for directors.
Dr. Chowdhury, age 61, has served as Senior Vice President, Chief Physician-Scientist, Respiratory Inflammation and Autoimmunity, Late Stage,
Research and Development Biopharmaceuticals, AstraZeneca, (NYSE: AZN) since April 2019. Prior to that he was Senior Vice President, Research and Development AstraZeneca Medimmune; Head of Respiratory Inflammation and Autoimmunity (RIA) Innovative
Medicine Early Development at Medimmune, from April 2018 to April 2019. From August 1997 to April 2018, he was at the United States Food and Drug Administration (FDA) where he held roles of increasing responsibility, including Director of the
Division of Pulmonary, Allergy, and Rheumatology Products at the FDAs Center for Drug Evaluation and Research (CDER). Dr. Chowdhury has a M.B., B.S. in Medicine from University of Dhaka, Dhaka Medical College, Bangladesh, and a Ph.D. in
Immunology from Memorial University of Newfoundland, Canada. He completed his residency training in Internal Medicine at the Wayne State University School of Medicine, Detroit, Michigan, and fellowship in Allergy and Immunology at the National
Institutes of Healths, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and is double board certified in Internal Medicine and Allergy and Immunology. The Board believes that Dr. Chowdhury is qualified to serve
on the Companys board of directors based on his extensive clinical trial and regulatory strategy expertise at the FDA and with the pharmaceutical industry.